MDPI and ACS Style
Nardin, C.; Hennemann, A.; Diallo, K.; Funck-Brentano, E.; Puzenat, E.; Heidelberger, V.; Jeudy, G.; Samimi, M.; Lesage, C.; Boussemart, L.;
et al. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). Cancers 2023, 15, 3564.
https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15143564
AMA Style
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L,
et al. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). Cancers. 2023; 15(14):3564.
https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15143564
Chicago/Turabian Style
Nardin, Charlée, Aymeric Hennemann, Kadiatou Diallo, Elisa Funck-Brentano, Eve Puzenat, Valentine Heidelberger, Géraldine Jeudy, Mahtab Samimi, Candice Lesage, Lise Boussemart,
and et al. 2023. "Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)" Cancers 15, no. 14: 3564.
https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15143564